Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Cash & Equivalents (2021 - 2025)

Krystal Biotech's Cash & Equivalents history spans 5 years, with the latest figure at $496.3 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 43.91% year-over-year to $496.3 million; the TTM value through Dec 2025 reached $496.3 million, up 43.91%, while the annual FY2025 figure was $496.3 million, 43.91% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $496.3 million at Krystal Biotech, up from $392.6 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $496.3 million in Q4 2025 and bottomed at $140.7 million in Q1 2023.
  • The 5-year median for Cash & Equivalents is $343.1 million (2021), against an average of $316.0 million.
  • The largest annual shift saw Cash & Equivalents crashed 52.56% in 2022 before it soared 155.08% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $341.2 million in 2021, then plummeted by 52.56% to $161.9 million in 2022, then skyrocketed by 121.33% to $358.3 million in 2023, then fell by 3.76% to $344.9 million in 2024, then surged by 43.91% to $496.3 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Cash & Equivalents are $496.3 million (Q4 2025), $392.6 million (Q3 2025), and $353.8 million (Q2 2025).